- Home
- XBIO vs KTTA Comparison
XBIO vs KTTA Comparison
Compare XBIO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- KTTA
- Stock Information
- Founded
- XBIO N/A
- KTTA 2020
- Country
- XBIO United States
- KTTA United States
- Employees
- XBIO N/A
- KTTA N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- KTTA Health Care
- Exchange
- XBIO Nasdaq
- KTTA Nasdaq
- Market Cap
- XBIO 4.9M
- KTTA 5.1M
- IPO Year
- XBIO N/A
- KTTA 2021
- Fundamental
- Price
- XBIO $2.99
- KTTA $0.72
- Analyst Decision
- XBIO Hold
- KTTA
- Analyst Count
- XBIO 1
- KTTA 0
- Target Price
- XBIO N/A
- KTTA N/A
- AVG Volume (30 Days)
- XBIO 47.7K
- KTTA 100.1K
- Earning Date
- XBIO 08-13-2025
- KTTA 08-19-2025
- Dividend Yield
- XBIO N/A
- KTTA N/A
- EPS Growth
- XBIO N/A
- KTTA N/A
- EPS
- XBIO N/A
- KTTA N/A
- Revenue
- XBIO $2,446,221.00
- KTTA N/A
- Revenue This Year
- XBIO $10.15
- KTTA N/A
- Revenue Next Year
- XBIO $11.11
- KTTA N/A
- P/E Ratio
- XBIO N/A
- KTTA N/A
- Revenue Growth
- XBIO N/A
- KTTA N/A
- 52 Week Low
- XBIO $2.20
- KTTA $0.65
- 52 Week High
- XBIO $5.27
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- XBIO 30.59
- KTTA 49.19
- Support Level
- XBIO $2.63
- KTTA $0.66
- Resistance Level
- XBIO $3.26
- KTTA $0.72
- Average True Range (ATR)
- XBIO 0.21
- KTTA 0.05
- MACD
- XBIO -0.08
- KTTA 0.00
- Stochastic Oscillator
- XBIO 8.17
- KTTA 50.37
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).